南财智讯7月27日电,诺诚健华(09969.HK)发布自愿公告,公司自主研发的TYK2变构抑制剂fadeucravacinib(ICP-488)用于治疗中重度斑块状银屑病的III期注册性临床试验成功达到主要终点,统计学显著且具临床意义,并同步达成多项次要终点。该研究为随机、双盲、安慰剂对照多中心试验,验证了ICP-488在疗效、安全性及耐受性方面的优势;其安全性特征与既往临床研究一致,未发现新...
Source Link南财智讯7月27日电,诺诚健华(09969.HK)发布自愿公告,公司自主研发的TYK2变构抑制剂fadeucravacinib(ICP-488)用于治疗中重度斑块状银屑病的III期注册性临床试验成功达到主要终点,统计学显著且具临床意义,并同步达成多项次要终点。该研究为随机、双盲、安慰剂对照多中心试验,验证了ICP-488在疗效、安全性及耐受性方面的优势;其安全性特征与既往临床研究一致,未发现新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.